EUCTR2008-005234-79-ITActive, not recruitingNot Applicable
Safety and efficacy of fondaparinux 1.5 mg in the prevention of venous thromboembolism in medical patients with severe renal insufficiency - ND
DIPARTIMENTO DI MEDICINA CLINICA - UNIVERSITA` DEGLI STUDI DELL`INSUBRIA0 sitesStarted: November 19, 2008Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •.Age > 60 years. Hospitalization for one of the following diseases: heart failure NYHA class III/IV, acute respiratory insufficiency, acute infection or acute inflammatory diseases (arthritis, connective tissue diseases or inflammatory bowel diseases) .at least four days of hospitalization . Renal insufficiency defined by a creatinine clearance between 20 and 50 ml/min calculated using the MDRD formula .written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •. Active Hemorrhage or in the previous three months .known hemorrhagic diathesis .platelet count < than 100.000 .Active treatment with unfractionated heparin, low molecular weight heparin or fondaparinux at therapeutic dosage or treatment with oral anticoagulant therapy. Previous administration of prophylactic doses of unfractionated heparin, low molecular weight heparin or fondaparinux from more than 48 hours .Life expectation < 1 month
Investigators
Similar Trials
Completed
Phase 3
Phase III study of efficacy of fondaparinux on the prevention of post-operative venous thromboembolism in patients undergoing with laparoscopic colorectal cancer surgery.Colorectal cancersJPRN-UMIN000008435Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group300
Completed
Not Applicable
Efficacy and safety of Fondaparinux for prevention of venous thromboembolism (VTE) after abdominal surgeryJPRN-UMIN000006543Kansai Medical University Hirakata hospital100
Terminated
Phase 4
Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal InsufficiencyMedical PatientsRenal InsufficiencyNCT00927602Università degli Studi dell'Insubria206
Active, not recruiting
Not Applicable
Fondaparinux population pharmacokinetic to morbid obese patients in post-operatory bariatric surgeryEUCTR2009-016417-15-FRCHU de SAINT-ETIENNE
Active, not recruiting
Not Applicable
Pharmacodynamics of Fondaparinux subcutaneous versus continuous intravenous infusion in critically ill patients with or without vasopressors.EUCTR2007-004911-79-BEcliniques Universitaires st luc-ucl